Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.
Anywhere
Joined July 2015
- Tweets249
- Following587
- Followers368
- Likes345
Ian Setliff retweeted
TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells dlvr.it/SrrW3Y
Ian Setliff retweeted
High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science.
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing frontiersin.org/article/10.3…
Ian Setliff retweeted
#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies.
Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified.
Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking go.nature.com/35O9Ali
Great place to do science!
We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies.
Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…
Ian Setliff retweeted
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…
Ian Setliff retweeted
More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: bit.ly/3t6f01H
Ian Setliff retweeted
Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: bit.ly/3rOhtNN CC: @Sanofi
Ian Setliff retweeted
Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: bit.ly/3kLkyeH @sanofi
We're looking for a computational immunologist. Come join us! careers.regeneron.com/6gQLWZ…
Ian Setliff retweeted
We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: bit.ly/3qWbLc5
Ian Setliff retweeted
With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: bit.ly/3dyViqs
Ian Setliff retweeted
Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: bit.ly/2MPuYgO
Great place to do science!
Pursue your passion for #science in a dynamic and innovative environment. Apply by December 1 to be a part of the Regeneron Postdoctoral Program.
Ian Setliff retweeted
The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: bit.ly/3lUkZ6e
Ian Setliff retweeted
Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: bit.ly/3mw6BRl
Ian Setliff retweeted
#SoundOn 📣. It’s impossible to be still, especially when we have the power to transform lives. See how we go from #SciencetoMedicine.